What is HC Wainwright’s Forecast for ACRS Q1 Earnings?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for Aclaris Therapeutics in a report released on Wednesday, May 14th. HC Wainwright analyst R. Selvaraju expects that the biotechnology company will post earnings per share of ($0.17) for the quarter. HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for Aclaris Therapeutics’ Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.60) EPS.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.07. Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%.

ACRS has been the topic of a number of other research reports. Scotiabank dropped their price objective on shares of Aclaris Therapeutics from $15.00 to $9.00 and set a “sector outperform” rating on the stock in a research note on Friday, May 9th. StockNews.com downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 8th. Finally, Cantor Fitzgerald initiated coverage on shares of Aclaris Therapeutics in a research report on Tuesday, March 18th. They set an “overweight” rating for the company. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $10.00.

Aclaris Therapeutics Stock Up 7.4%

ACRS opened at $1.31 on Thursday. The firm has a market capitalization of $141.85 million, a P/E ratio of -2.52 and a beta of 0.42. The firm’s 50 day moving average is $1.36 and its 200-day moving average is $2.23. Aclaris Therapeutics has a 52-week low of $0.95 and a 52-week high of $5.17.

Hedge Funds Weigh In On Aclaris Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. ExodusPoint Capital Management LP acquired a new position in Aclaris Therapeutics in the fourth quarter worth $26,000. Invesco Ltd. acquired a new position in Aclaris Therapeutics in the fourth quarter worth $28,000. Graham Capital Management L.P. acquired a new position in Aclaris Therapeutics in the fourth quarter worth $35,000. Commonwealth Equity Services LLC acquired a new position in Aclaris Therapeutics in the fourth quarter worth $36,000. Finally, Alpine Global Management LLC acquired a new position in Aclaris Therapeutics in the fourth quarter worth $38,000. Institutional investors and hedge funds own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.